This program is funded by an independent grant from Pfizer Global Medical Grants. This online education program has been designed solely for healthcare professionals globally. The content is not available for healthcare professionals in the United States or Canada.
Join renowned experts Professor David Livermore and Professor Karen Burns for this free online session focused on the latest advances in the global fight against antibiotic resistance. This session is designed for healthcare professionals worldwide who are looking to enhance their understanding of how antibiotic resistance is spreading and what can be done to manage it effectively. Addressing Metallo-β-Lactamase (MBL)-producing bacteria as a key example, our expert speakers will explore strategies for diagnosing and treating resistant infections. Participants will gain insights into laboratory techniques, antimicrobial therapies, and strategies for managing resistant pathogens, ultimately contributing to global efforts to curb the growing threat of antibiotic resistance.
Optimizing Diagnostic Strategies for MBL-Producing Bacterial Infections
Understand the critical role of diagnostic testing in the rapid detection of MBL-producing bacterial infections to ensure early and accurate diagnosis. Attendees will learn how to select between genotypic and phenotypic laboratory tests, with a clear understanding of the advantages and limitations of each method. The session will cover accurate interpretation of test results to confirm the presence of MBL-producing bacteria, aiding in effective treatment and infection control.
Communicate with Patients and Families:
Enhance your ability to counsel patients and their families on the impact of MBL-producing infections. Understand how to explain treatment options, the importance of therapy adherence, and the need for ongoing monitoring.
Faculty
Professor David Livermore
David Livermore earned his BSc in 1978 and PhD in 1983. He worked at the London Hospital Medical College until 1997, then joined the Health Protection Agency (now Public Health England), becoming Director of its Antibiotic Resistance Monitoring and Reference Laboratory in 1998. In 2011, he was appointed Professor of Medical Microbiology at the University of East Anglia, while also serving as Public Health England’s Lead on Antibiotic Resistance.
His research focuses on the evolution of antibiotic resistance, with a particular interest in beta-lactamases, including the proliferation of CTX-M enzymes and NDM-1 carbapenemases. He has served on multiple advisory boards and publishes widely on antimicrobial resistance.
Professor Karen Burns
Professor Karen Burns is a Consultant Clinical Microbiologist and the Lead Consultant for Infection Prevention & Control at Beaumont Hospital, Dublin, Ireland. She is also an Honorary Clinical Associate Professor at the Royal College of Surgeons in Ireland University of Medicine & Health Sciences. Her research interests include surveillance of healthcare-associated infections, antimicrobial resistance and consumption, infection prevention & control, Carbapenemase-producing Enterobacterales (CPE), and antimicrobial stewardship.
Disclosures:
Below is a listing of all individuals who are involved in the planning and implementation of this accredited continuing education activity. All relevant financial relationships listed for these individuals have been mitigated.
Karen Burns has no relevant financial relationships with ineligible companies to disclose and no unapproved product related discussions to disclose.
David Livermore: Advisory Boards or Consultancy for AdVanz, Antabio, AstraZeneca, Centauri, GenPax, Mutabilis, Paion, ParaPharm, Sumitovant, Summit, Thermofisher, Wockhardt, Zambon, Paid lectures – bioMérieux, GSK, Merck/MSD, Pfizer, and Shionogi. Relevant shareholdings or options – Dechra, GenPax, GSK, Merck and Revvity. Nominated holdings in Arecor Therapeutics, Celadon Pharmaceuticals, Destiny Pharma, Genedrive, Genincode, Oxford BioDynamics, Optibiotix Health, Probiotix Health, Rua Life Sciences, Skinbiotherapeutics and VericiDx.
Current Concepts Institute/MedAll staff and the planners and reviewers of this educational activity have no relevant financial or non-financial interests to disclose.
Unapproved and/or off-label use disclosure
Current Concepts Institute/MedAll requires CE faculty to disclose to the participants:
1. When products or procedures being discussed are off-label, unlabelled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
2. Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.
Accreditation statement
AMA PRA Category 1 Credits™ are available for this activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Current Concepts Institute and MedAll Education. Current Concepts Institute is accredited by the ACCME to provide continuing medical education for physicians.
Current Concepts Institute designates this online activity a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity
This continuing education activity is active starting 27th November 2024 and will expire on 27th November 2025. Estimated time to complete this activity: 1.5 hours.